Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,281 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Biologic Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya

NCT00666380
View directory record Official record
Conditions
Malaria
Interventions
Plasmodium falciparum Malaria Protein 010 (FMP010)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 3, 2026, 11:29 AM EDT
Not listed Phase 1 Interventional

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

NCT00641160
View directory record Official record
Conditions
Nonhematologic Malignancies
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Metronome Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
114
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 3, 2026, 11:29 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study

NCT01472094
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 3, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 3, 2026, 11:29 AM EDT
Active, not recruiting Not applicable Interventional

Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial

NCT06864208
View directory record Official record
Conditions
Weight, Body Weight, Weight Bias, Weight Stigma, Physiological Stress, Biological Markers of Stress, Biological Markers of Inflammation, Eating Behaviors
Interventions
Behavioral Weight Management, Weight Bias Internalization
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 3, 2026, 11:29 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

NCT04115748
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Covina, California • Brandon, Florida • DeBary, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

NCT00765076
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 3, 2026, 11:29 AM EDT
Withdrawn No phase listed Observational

Circadian RA Study in Rheumatoid Arthritis Subjects

NCT03178955
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

NCT02771340
View directory record Official record
Conditions
Uveal Melanoma, Choroid Neoplasm
Interventions
ICON-1
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Leawood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 3, 2026, 11:29 AM EDT
Terminated Not applicable Interventional

Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions

NCT01452516
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Interventions
nanOss Bioactive Bone void filler, Interbody FCage
Device
Lead sponsor
Pioneer Surgical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 3, 2026, 11:29 AM EDT
Recruiting Phase 3 Interventional

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

NCT07852338
View directory record Official record
Conditions
Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions
All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks., Standard wound care for diabetic foot ulcers, Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure
Biological · Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

NCT03345849
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 3, 2026, 11:29 AM EDT
Completed No phase listed Observational

The Biologic Basis of Hernia Formation

NCT01099033
View directory record Official record
Conditions
Hiatal Hernia, Paraesophageal Hernia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 3, 2026, 11:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Eye Institute Biorepository for Retinal Diseases

NCT01496625
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

NCT01374971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy
Drug · Procedure
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

NCT03104699
View directory record Official record
Conditions
Advanced Cancer, Cervical Cancer
Interventions
AGEN2034
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 3, 2026, 11:29 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 3, 2026, 11:29 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

NCT04294628
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

NCT05483075
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HCP-Guided Exercise Training Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 3, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00015912
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Interventions
recombinant interferon alfa, thalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 3, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Aspire2B Personalization Pilot Study Program

NCT06191822
View directory record Official record
Conditions
App Proficiency, Behavior, Lifestyle
Interventions
Nutrition, Fitness, Sleep
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 3, 2026, 11:29 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00020722
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 3, 2026, 11:29 AM EDT